Holistic approaches to prostate cancer

Alternative and Complementary Therapies

Volumn 14, Issue 4, 2008, Pages 164-180

  Yarnell, Eric ^a,b   Abascal, Kathy ^c  

^a Botanical Medicine Academy

^b BASTYR UNIVERSITY   (United States)

^c Botanical Medicine Academy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 50049089208     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/act.2008.14407     Document Type: Article

References (114)

1. Garfinkel L. Cancer statistics and trends. In: Murphy GP, Lawrence W Jr, Lenhard RE Jr, eds. American Cancer Society Textbook of Clinical Oncology, 2nd ed. Atlanta: American Cancer Society, 2005:1-9.
2. Gu F, XiaT, Kong X. Preliminary study of benign prostatic hyperplasia and prostatic cancer in China. Urology 1994;44:688-691.
3. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for the implications of the multistep development of prostate cancer. J Urol 1990;143:742-746.
4. Shimazu H1 Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-966.
5. Moul JW, Douglas TH, McCarthy WF, McLcod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996;155:1667-1673.
6. Tovar-Guzmán V, Hernández-Girón C, López-Ríos O, Lazcano-Ponce EC. Prostate cancer mortality trends in Mexico, 1980-1995. Prostate 1999;39:23-27.
7. Montie JE, Pienta KJ. A unifying model to explain the increased incidence and higher mortality of prostate cancer in black men. Urology 1999;53:1073-1076.
8. Richert-Boe KE, Weinmann S, Shapiro JA,et al. Racial differences in treatment of early-stage prostate cancer. Urology 2008;71:1172-11.76.
9. WilloughbyJ. Primal prescription. Eating Well May/June 1991:52-59.
10. Griffiths K, Morton MS, Nicholson RI. Androgens, androgen receptors, anti androgens and the treatment of prostate cancer. Eur Urol 1997;32(suppl3):24-40.
11. Robinson MRG, Smith PH, Richards B, et al. The final analysis of the EORTCgenito-urinary tract cancer co-operative group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995;28:273-283.
12. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998;152:1-9.
13. Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent andro gen suppression: Rationale and clinical experience. In: Schröder FH, ed. Recent Advances in Prostate Cancer and BPI I. New York: Parthenon Publishing Group, 1997:109-119.
14. Cury FL, Souhami L, Rajan R, et al. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer, hit J Radiat Oncol Biol Phys 2006;64:842-848.
15. Lissoni P, Cazzaniga M, Tancini G, et al. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: Efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur Urol 1997;31:178-181.
16. Mills E, Wu P, Seely D.Guyatt G. Melatonin in the treatment ofcancer: A systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005;39:360-366.
17. Igtichi K, Okumura N, Usui S, et al. Myristoleic acid, a cytotoxic componenl in lhe extract from Serenoa repetis, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001;47:59 65.
18. Iehlé C, Délos S, Guirou O, et al. Human prostatic steroid 5 alpha -reductase isoforms a comparative study of selective Inhibitors. J Steroid Bio chcm Molcc Biol 1995;54:273-279.
19. Sultan C, Terraza A, Devillier C,el al. Inhibition of androgen metabolism and binding by a liposterolic extract of '"Serenoa repens B" in human foreskin fibroblasts.) Steroid Biochem 1984;20:515-519.
20. Délos S, Carsol JL, Ghazarossian E, ct al. Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem MoI Biol 1995;55:375-383.
21. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy. Eur Urol 1.992;21.:309-31.4.
22. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar) and Serenoa repens (Penmixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247-252.
23. Sökeland J, Albrecht J. A combination of sabal and Urtica extracts vs. finasteride in BPH (stage 1 to 11 according to Aiken): A comparison of the therapeutic efficacy in a one-year double-blind study. Urologe [A] 1997; 36:327-333.
24. Fcltcr HW.The Eclectic Materia Medica, Pharmacology and Therapeutics. Sandy, OR: Eclectic Medical Publications, 1922; reprinted 1998.
25. Hartman RW, Mark M, Soldáti F. Inhibition of 5-alpha-rcductase and aromatase by PHI.-00801 (Prostatonin), a combination of PY 102 (Pyge urn afrkanum) and UR 1.02 (Urtica dioica) extracts. Phytomedicine 1996; 3:121.-128.
26. Gansser D, Spiteller G. Plant constituents interfering with human sex hormone-binding globulin: Evaluation of a test method and its application to Urtica dioica root extracts. Z Naturforsch 1995;50c:98-104.
27. Wagner H, Geiger WN, Boos G, Samtleben R. Studies on the binding of Urtica dioica agglutinin (UDA) and other lectins in an in vitro epidermal growth factor receptor test. Phytomedicine 1995;2:287-290.
28. Simons AJ, Dawson IK, Duguma B, et al. Passing problems: Prostate and prunus. HerbàlGram 1998;43:49 53.
29. Messina M, Barnes S.The role of soy products in reducing risk of cancer. J Nail Cancer Inst 1991 ¡83:541 546.
30. Jordan VC, Milta.l S, Gosden B, el al. Structure-activity relationships of estrogens. Environ Health Perspect 1985;61:97 110.
31. Goldin BR, Adlercreutz H, Gorbach SL, et al. The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. Am J Clin Nutr 1986;44:945-953.
32. Yan L, Spitznagel EL. Meta analysis of soy food and risk of prostate cancer in men. Int J Cancer 2005;117:667-669.
33. Kurzer MS, Xu X. Dietary phytoestrogens. Ann Rev Nutr 1997; 17:353 381.
34. Kaufman PB, Duke JA, Brielmann H, et al. A comparative survey of leguminous plants as sources of the isoflavones genistein and daidzein: Implications for human nutrition and health. J Altern Complement Med 1997;3:7-12.
35. Stephens FO. Phytoestrogens and prostate cancer: Possible preventive role. Med J Aust 1997;167:138-140.
36. Severson RK, Nomura AMY, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989;49:1857-1860.
37. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity and body size in blacks, white and Asians in the US and Canada. J Nail Cancer Inst 1995;87:652 661.
38. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence?The Advenrisr Health Study (United States). Can ccr Causes Control 1998;9:553-557.
39. EcoNugenics Inc. EcoNugenics Inc. report on Ecogen 851. Cancer Communication Newsletter 1997;Oct:16.
40. Guo Y, Wang S, Hoot DR, Clinton SK. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007;18:408-417.
41. Shenouda NS, Zhou C, Browning JD, et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 2004;49:200-208.
42. Hamilton-Reeves JM, Rebello SA, Tilomas W, et al. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receplor-beta expression or serum hormonal profiles in men al high risk of prostate cancer. J Nutr 2007;137:1769-1775.
43. Aldercreutz H, Makela S, Pylkkanen L, et al. Dietary phytoestrogens and prostate cancer. Proc Annu Meet Am Assoc Cancer Res 1995;36:687.
44. Raschke M, Rowland IR, Magee PJ, Pool-Zobel BL. Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress. Carcinogenesis 2006;27:2322-2330.
45. Hedlund TE, Maroni PD, Ferucci PG et al. Long term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr 2005;135:1400-1406.
46. Marks LS, Kojima M, Demarzo A, et al. Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue. Urology 2004;64:765-771.
47. Joniau S, Goeman L, Roskams T, et al. Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. Urology 2007;69:1102-1106.
48. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity ofan estrogenic herbal combination (PC-SPES) in prostate cancer. New Engl J Med 1998;339:785 791.
49. Blumenlhal M. The rise and fall of PC-SPES: New generation of herbal supplement, adulterated product, or new drug? lntegr Cancer Ther 2002; 1:266-270.
50. Shabbir M, Love J, Montgomery B. Phase I trial of PC Spes2 in advanced hormone refractory prostate cancer. Oncol Rep 2008; 19:831-835.
51. Brown DJ. Vitex agnus castus clinical monograph. Q Rev Nat Med 1994;Summer:111-121.
52. Jarry H,Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: Direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994;102:448-454.
53. Merz PG, Gorkow C, Schrödter A, et al. The effects of a special Agnus castus extract (BP1095E1.) on prolactin secrelion in healthy male subjects. Exp Clin Endocrinol Diabetes 1996;104:447 453.
54. Horrobin DF. Prolactin. Medical and Technical Publishing Co Ltd., Lancaster, UK, 1974.
55. Bhargava SK. Anliandrogenic effects of a flavonoid-rich fraction of Vitex negando seeds: A histological and biochemical study in dogs. J Ethnopharmacol 1989;27:327-339.
56. Kelter HW, Lloyd JU. King's American Dispensatory,vol. 11, 18th ed. Sandy, OR: Eclectic Medical Publications, 1898;reprinted 1997:2056.
57. Ellingwood F. American Materia Medica, Therapeutics and Pharmacognosy, 11th ed. Sandy, OR: Eclectic Medical Publications, 1919; reprinted 1998: 478-479.
58. Konety BR, Johnson CS, Trump DL, Getzenberg RII. Vitamin D in the prevention and treatment of prostale cancer. Sem Urol Oncol 1999; 17:77 84.
59. Schwartz GG, Hylka BS. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 1990;10:1307.
60. 2 vitamin D in relation to prostate cancer: A hypothesis. Cancer Causes Control 1998;9:567-582.
61. Hanchetle CL, Schwartz GG. Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861.
62. Krill D, Stoner J, Konety BR, et al. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology 1999;54:171-177.
63. Kibel AS, Isaacs SD, Isaacs WB, Bova GS. Vitamin D receptor polymorphisms and lethal prostate cancer.J Urology 1998;160:1405-1409.
64. Li H, Stampfer MJ, Hollis JB,et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007;4(3):e103.
65. 3 (calcitriol). J Urol 1998;159:2035-2040.
66. Osborn JL, Stamey TA, Hancock S, et al. Phase 11 trial of oral 1,25 dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1998;1:195-198.
67. Heron S, Yarnell E. Recurrent kidney stones: A naturopathic approach. Altern Complement Ther 1998;4:60-67.
68. 3 and platinum drugs act synergist ically Io inhibit the growlh of prostate cancer lines. Clin Cancer" Res 1999;5:695 703.
69. Hathcock JN, Shao A, Vielh R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6 18.
70. von Holtz RL, Fink CS, Awad AB. Beta-sitoslerol activates lhe sphingomyelin cycle and induces apoplosis in LNCaP human prostate cancer cells. Nutr Cancer 1998;32:8-12.
71. Endogenous Hormones, Prostate Cancer Collaborative Group; Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-183.
72. Carpenter WR, Robinson WR, Godley PA. Getting over testosterone: Postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Insl. 2008;100:158-159.
73. Jones JA, Nguyen A, Straub M, et al. Use of DHEA in a patient with advanced prostate cancer: A case report and review. Urology 1997;50:784-788.
74. Shah SA, Sander S, White CM, et al. Evaluation of echinacea for the prevention and treatment of the common cold: A meta-analysis. Lancet Infect Dis 2007;7:473-480.
75. Lersch C, Zeuner M, Bauer A, et al. Nonspecific immunostimulation with low doses of cyclophosphamide (LDCY), thymostimulin and Echinacea purpurea extracts (Echinacin) in patients with far advanced colorectal cancers: Preliminary results. Cancer Invest 1992;10:343-348.
76. Lersch C, Zeuner M, Bauer A, et al. Stimulation of the immune response in outpatients with hepatocellular carcinomas by low doses of cyclophosphamide (LDCY), Echinacea purpurea extracts (Echinacin) and thymostimulin. Arch Geschwulstforsch 1990;60:379-383.
77. Kupin VJ. Eleutherococcus and other biologically active modifiers in oncology [pamphlet], Moscow: Medexport, 1984.
78. Monakhov BV Decrease in toxic effect of some antiblastic drugs using eleutherococcus extract [in Russian]. Voprosy Onkol 1967;13:71-76.
79. Tsyrlina EV The effect of chemotherapeutic drugs in combination with Eleutherococcus senticosus on induction and development of tumor metastases. Voprosy Onkol 1965;11:70-77.
80. Kupin VJ, Polevaya YB, Sorokin AM. Eleutherococcal extract treatment for immunostimulation in cancer patients. Voprosy Onkol 1986;32:21-26.
81. Scaglionc F, Ferrara F, Dugnani S, et al. Immunomodulatory effects of two extracts of Panax ginseng CA Meyer. Drugs Exp Clin Res 1990;16: 537-542.
82. Yun T K, Choi SY. A case -control study of ginseng intake and cancer. Int J Epidemiol 1990;19:871-876.
83. Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: A case-control study on 1987 pairs. Cancer Epidemiol BiomarkersPrev 1995;4:401-408.
84. Yun TK, Choi SY. Non organ specific cancer prevention of ginseng: A prospective study in Korea. Int J Epidemiol 1998;27:359-364.
85. Shankar AH, Prasad AS. Zinc and immune function: The biological basis o I'altered resistance to infection. Am J Clin Nutr 1998;68(suppl):447s-463s.
86. Solomons NW. Mild human zinc deficiency produces an imbalance between cell-mediated and humoral immunity [review]. Nutr Rev 1998;56:27-28.
87. Korkina L, Osato JA, Chivilyeva I, et al. Radioprotective and antioxidant effecls of zinc aspartate and Bio-Normalizer in children with acule myelo-and lympholeukemias.Nutrition 1995(suppl):555 558.
88. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998;35:285-296.
89. D ubi N, Gheber L, Fishman D, et al. Extracellular zinc and zinc-citrate, acting through a putative zinc sensing receptor,regulate growth and survival of prostate cancer cells. Carcinogenesis 2008;Feb; epub ahead of print.
90. Ogunlewe JO, Osegbe DN. Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer 1989;63:1388-1392.
91. West DW, Slattcry ML, et al. Adult dietary intake and prostate cancer risk in Utah: A case-control study with special emphasis on aggressive tumors. Cancer Causes Control 1991;2:85-94.
92. Wang M, Cao J, Fahim MS. Intraprostatic injection of zinc salt as a treat ment for benign prostatic hyperplasia [abstract 44]. J Androl 1997;1.8:P35.
93. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial.JAMA 1996;276:1957-1963.
94. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. BrJ Urol 1998;81:739-744.
95. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983;ii:130-134.
96. Kiremidjian-Schumacher L, Roy M, Wishe HI, et al. Regulation of cellular immune responses by selenium. Biol Trace Elem Res 1992;33:23-35.
97. Nelson MA, Porterfield BW, Jacobs ET, Clark LC. Selenium and prostate cancer prevention [review]. Sem Urol Oncol 1999;17:91 96.
98. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 1994;330:1029-1035.
99. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-446.
100. Pantuck AJ, Lepperr JT, Zomorodian N, et al. Phase II study of pome granate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12:4018-4026.
101. Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not im pair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: Comparison with grapefruit juice. J Clin Pharmacol 2007;47:286-294.
102. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995;87:348-353.
103. Guess BW, Scholz MC, Strum SB, et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: A phase II pilot study. Prostate Cancer Prostatic Dis 2003;6:301-304.
104. Jankun J, Selman SH, Swiercz R, et al. Why drinking green tea could prevent cancer. Nature 1.997;387:561.
105. Gupta S, Ahmad N, Mukhtar H. Proslate cancer chemoprevention by green tea [review]. Sem Urol Oncol 1999;17:70-76.
106. Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. Clin Cancer Res 1998;4:153-156.
107. Sporn M, Roberts S. Role of retinoids in differential ion and carcinogenesis. Cancer Res 1983;43:3034-3040.
108. Whelan P. Retinoic acid and prostatic cancer cell growth [review]. In: Newling DWW, Jones WG, eds. EORTC Genitourinary Group Monograph 7: Prostate Cancer and Testicular Cancer. New York Wiley-Liss, 1990: 117-120.
109. Habib FK, Busuttill A, Robinson RA, et al. 5-Alpha reductase activity in human prostate cancer is related to the histological differentiation of the tumour. Clin Endocrinol 1985;23:431-438.
110. Whelan P, Walker BE, Kelleher J. Zinc, vitamin A and prostatic cancer. Br J Urol 1983;55:525 528.
111. Spiegel D, Bloom JR, Kracmcr HC, Gotthcil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;ii:888 891.
112. Nielsen NR, Krisrensen TS, Zhang ZF, et al. Sociodemographic status, stress, and risk of prostate cancer: A prospective cohort study. Ann Epidemiol 2007; 17:498 502.
113. Lissoni P, Paolorossi F,Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32A:1340-1343.
114. Coulter AH. Promoting self responsibility for health: The Helios Health Center. Altern Complement Ther 1999;5:286-294.